Item 8.01. Other Events.
On January 9, 2023, the Company issued a press release announcing the receipt of
feedback from a pre-Investigational New Drug supplemental Type C response from
the U.S. Food and Drug Administration and providing further detail with respect
to anticipated key milestones that the Company expects to achieve in 2023
regarding its PGN-600 program. The full text of the press release is attached as
Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by
reference.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
99.1 Press Release, dated January 9, 2023
104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
--------------------------------------------------------------------------------
© Edgar Online, source Glimpses